文献速递乳腺癌放疗

自适应计划算法指导IMRT与3DCRT用于淋巴结阳性乳腺癌区域淋巴结照射的临床效果

Clinical Effectiveness of an Adaptive Treatment Planning Algorithm for Intensity Modulated Radiation Therapy Versus 3D Conformal Radiation Therapy for Node-Positive Breast Cancer Patients Undergoing Regional Nodal Irradiation/Postmastectomy Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-07-22

本研究回顾性评估一项自适应治疗计划算法(TPA)在淋巴结阳性乳腺癌区域淋巴结照射(RNI)中的应用,该算法先采用3DCRT,当危及器官(OAR)约束不满足时转为IMRT。

要点

  • 自适应TPA以平均心脏剂量≤500 cGy、同侧肺V20≤35%为约束决定是否改用IMRT。
  • IMRT与3DCRT的4年局部区域复发率分别为2.8%和1.8%,差异无统计学意义。
  • 3例出现锁骨上淋巴结失败,其中仅1例位于锁骨上后区。

核心结论

  • 当3DCRT无法满足关键OAR约束时,按自适应TPA改用IMRT未改变失败模式,且高级别毒性罕见,支持IMRT在保持治疗比方面的作用。

研究设计与样本

  • 74%行乳房切除术后放疗、26%行保乳术后放疗;168例最终接受3DCRT、72例接受IMRT。
  • 处方剂量为2 Gy/次,靶区前瞻性勾画并包括内乳淋巴结。

主要发现

  • 共7例局部区域复发(IMRT 2例、3DCRT 5例),4年局部区域复发率IMRT 2.8%对3DCRT 1.8%(P=.99)。
  • 3例发生锁骨上淋巴结失败(IMRT 2例、3DCRT 1例),其中1例位于锁骨上后区(SCL-post)。
  • IMRT与3DCRT之间失败模式无差异。

关键数值与推荐

  • OAR约束:平均心脏剂量≤500 cGy;同侧肺V20≤35%。
  • 3DCRT无法满足上述约束时改用IMRT。
  • 处方剂量2 Gy/次,靶区包括内乳淋巴结。

临床怎么用

  • 对淋巴结阳性乳腺癌RNI患者可先以3DCRT计划评估OAR约束,不满足时按预设标准转为IMRT。
  • 该算法可在满足心脏和肺剂量约束的同时维持肿瘤控制,且未观察到高级别毒性增加。

局限性

  • 为单中心回顾性分析,IMRT与3DCRT组间比较非随机,样本量有限。
  • 随访时间与毒性评估细节在摘要中未完整报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Clinical trials support adjuvant regional nodal irradiation (RNI) after breast-conserving surgery or mastectomy for patients with lymph node-positive breast cancer. Advanced treatment planning techniques (eg, intensity modulated radiation therapy [IMRT]) can reduce dose to organs at risk (OARs) in this situation. However, uncertainty persists about when IMRT is clinically indicated (vs 3-dimensional conformal radiation therapy [3DCRT]) for RNI. We hypothesized that an adaptive treatment planning algorithm (TPA) for IMRT adoption would allow OAR constraints for RNI to be met when 3DCRT could not without significantly changing toxicity and locoregional recurrence (LRR) patterns. METHODS AND MATERIALS: Since 2013, all RNI patients also underwent an adaptive TPA that began with 3DCRT and then changed to IMRT when OAR constraints (mean heart dose ≤500 cGy; ipsilateral lung V20 ≤35%) could not be met. Patients received 2 Gy/d to the prospectively contoured target volumes (including internal mammary nodes). We retrospectively evaluated the dosimetry and clinical outcomes of the treatment groups (IMRT vs 3DCRT). The primary endpoint was the cumulative incidence of LRR as the site of first recurrence, and we specifically address patterns of failure based on dose to the posterior supraclavicular nodal region (SCL-post). RESULTS: Two hundred forty patients (60% stage III; mean 4.0 + nodes) underwent an adaptive-TPA for RNI after mastectomy (74%) or breast-conserving surgery (26%), resulting in 168 patients treated with 3DCRT and 72 patients treated with IMRT. There were 7 LRRs (2 IMRT, 5 3DCRT) resulting in 4-year LRR of 2.8% for IMRT versus 1.8% for 3DCRT (P = .99). Three patients (2 IMRT, 1 3DCRT) had SCL nodal failures (1 in the SCL-post). CONCLUSIONS: An adaptive TPA for use of IMRT when 3DCRT does not meet critical OAR constraints resulted in rare high-grade toxicity and no difference in failure patterns between patients treated with IMRT and 3DCRT. These data should provide reassurance that IMRT maintains the therapeutic ratio by preserving cancer control outcomes without excess toxicity when 3DCRT fails to meet OAR constraints.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Bazan JG, Healy E, Beyer S, et al. Clinical Effectiveness of an Adaptive Treatment Planning Algorithm for Intensity Modulated Radiation Therapy Versus 3D Conformal Radiation Therapy for Node-Positive Breast Cancer Patients Undergoing Regional Nodal Irradiation/Postmastectomy Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020. PMID: 32711036. doi:10.1016/j.ijrobp.2020.07.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。